Nautilus Biotechnology (NAUT) Other financing activities (2020 - 2021)

Nautilus Biotechnology's (NAUT) quarterly Other financing activities came in at $47000.0 in Q3 2021, down 98.61% year-on-year from $3.4 million in Q3 2020, and down 99.22% quarter-over-quarter from $6.0 million in Q2 2021.

Nautilus Biotechnology (NAUT) Other financing activities (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has disclosed Other financing activities across 2 years of filings, most recently posting $47000.0 for Q3 2021.

  • Other financing activities for Q3 2021 came in at $47000.0, down 98.61% year-over-year; the trailing twelve-month figure through Jun 2022 was $47000.0 (down 99.68% YoY), and the FY2021 annual result was $8.1 million, changed N/A from the prior year.
  • Other financing activities came in at $47000.0 for Q3 2021 at Nautilus Biotechnology, down from $6.0 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $6.0 million in Q2 2021 to a low of $47000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 Nautilus Biotechnology 289.99 Mn 194.12 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 47,000.00
Sep 30, 2021 47,000.00
Jun 30, 2021 6.01 Mn
Jun 30, 2021 6.01 Mn
Mar 31, 2021 2.07 Mn
Mar 31, 2021 2.07 Mn
Dec 31, 2020 3.38 Mn
Dec 31, 2020 3.38 Mn
Sep 30, 2020 3.38 Mn
Sep 30, 2020 3.38 Mn
Jun 30, 2020 200,000.00
Jun 30, 2020 200,000.00